S&P 500
(0.11%) 5 254.20 points
Dow J
(0.01%) 39 763 points
Nasdaq
(0.04%) 16 407 points
Oil
(1.70%) $82.73
Gas
(0.76%) $1.731
Gold
(0.89%) $2 232.40
Silver
(0.97%) $24.99
Platinum
(1.43%) $922.75
USD/EUR
(0.28%) $0.926
USD/NOK
(0.50%) $10.82
USD/GBP
(0.04%) $0.792
USD/RUB
(0.25%) $92.68

Realtime updates for Paratek Pharmaceuticals [PRTK]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated20 Sep 2023 @ 16:00

1.83% $ 2.23

Live Chart Being Loaded With Signals

Commentary (20 Sep 2023 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use...

Stats
Today's Volume 4.48M
Average Volume 599 679
Market Cap 127.83M
EPS $0 ( 2024-03-14 )
Next earnings date ( $0 ) 2024-05-07
Last Dividend $0.667 ( 2014-10-31 )
Next Dividend $0 ( N/A )
P/E -2.01
ATR14 $0.0250 (1.12%)
Insider Trading
Date Person Action Amount type
2023-09-21 Baylor-henry Minnie Sell 32 800 Common Stock
2023-09-21 Baylor-henry Minnie Sell 26 400 Common Stock
2023-09-21 Baylor-henry Minnie Sell 12 800 Stock option (right to buy)
2023-09-21 Hoffmann Rolf K Sell 64 000 Common Stock
2023-09-21 Hoffmann Rolf K Sell 20 000 Common Stock
INSIDER POWER
-63.66
Last 96 transactions
Buy: 1 606 755 | Sell: 5 363 965

Volume Correlation

Long: 0.14 (neutral)
Short: 0.00 (neutral)
Signal:(59.187) Neutral

Paratek Pharmaceuticals Correlation

10 Most Positive Correlations
PAIC0.948
SVOK0.947
BIOL0.912
RMRM0.909
YMAB0.899
SVAC0.89
AVCT0.883
TSP0.879
UK0.876
GAINL0.876
10 Most Negative Correlations
BOCH-0.954
NETE-0.938
MMAC-0.912
RAVN-0.903
SHSP-0.9
LMRK-0.894
QADA-0.878
VLYPO-0.862
AMRB-0.862
PODD-0.858

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Paratek Pharmaceuticals Correlation - Currency/Commodity

The country flag 0.07
( neutral )
The country flag -0.28
( neutral )
The country flag 0.00
( neutral )
The country flag 0.06
( neutral )
The country flag -0.27
( neutral )
The country flag -0.40
( neutral )

Paratek Pharmaceuticals Financials

Annual 2022
Revenue: $150.79M
Gross Profit: $127.73M (84.71 %)
EPS: $-1.170
Q2 2023
Revenue: $38.06M
Gross Profit: $33.69M (88.52 %)
EPS: $-0.250
Q1 2023
Revenue: $29.21M
Gross Profit: $22.96M (78.62 %)
EPS: $-0.350
Q4 2022
Revenue: $72.63M
Gross Profit: $62.32M (85.80 %)
EPS: $-0.130

Financial Reports:

No articles found.

Paratek Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Paratek Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $15.96 2014-05-21
Last Dividend $0.667 2014-10-31
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 4 --
Total Paid Out $40.59 --
Avg. Dividend % Per Year 0.00% --
Score 1.84 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-04-08)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
1.84
Pay Frequency
Bi-Monthly
Yearly Payout
Year Amount Yield
2014 $40.59 172.60%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.4001.500-8.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.4601.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM0.3691.5007.0110.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM0.5190.800-2.40-1.923[1 - 3]
quickRatioTTM0.4200.800-2.23-1.786[0.8 - 2.5]
cashRatioTTM0.2111.5009.9410.00[0.2 - 2]
debtRatioTTM1.782-1.50010.00-10.00[0 - 0.6]
interestCoverageTTM-2.361.000-1.986-1.986[3 - 30]
operatingCashFlowPerShareTTM-0.4052.00-0.135-0.270[0 - 30]
freeCashFlowPerShareTTM-0.4072.00-0.203-0.407[0 - 20]
debtEquityRatioTTM-1.290-1.500-5.167.74[0 - 2.5]
grossProfitMarginTTM0.8491.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-0.2661.000-7.31-7.31[0.1 - 0.6]
cashFlowToDebtRatioTTM-0.08941.000-1.608-1.608[0.2 - 2]
assetTurnoverTTM1.1510.8005.664.53[0.5 - 2]
Total Score-0.1000

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-1.9031.000-0.2930[1 - 100]
returnOnEquityTTM0.3692.508.0810.00[0.1 - 1.5]
freeCashFlowPerShareTTM-0.4072.00-0.136-0.407[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.4052.00-0.135-0.270[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.1121.500-2.590[0.5 - 2]
operatingCashFlowSalesRatioTTM-0.1381.000-5.960[0.1 - 0.5]
Total Score-0.0678

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators